Welcome to our dedicated page for Rapid Micro Biosystems SEC filings (Ticker: RPID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rapid Micro Biosystems, Inc. filings document the company's microbial quality-control automation business, governance matters and capital structure. Form 8-K reports furnish operating results, preliminary revenue updates, Regulation FD disclosures about the Growth Direct platform, and material agreements such as term-loan financing secured by company assets and related warrants for Class A common stock.
Proxy filings cover annual meeting procedures, stockholder voting matters, board governance and executive compensation disclosures. Other material-event reports address officer-transition and compensatory-arrangement disclosures, while recent cover pages identify the company as an emerging growth company for Exchange Act reporting purposes.
Rapid Micro Biosystems, Inc. (RPID) received an updated ownership disclosure showing that investment entities affiliated with Endeavour Medtech collectively report beneficial ownership of 2,257,099 shares of Class A common stock, representing 5.7% of the class, based on 39,823,026 shares outstanding as of October 31, 2025.
The shares are held of record by Endeavour Medtech Growth II LP (2,217,190 shares) and Endeavour Medtech Growth II Parallel LP (39,909 shares), with Endeavour Medtech II GP Limited as general partner. The reporting group certifies the holdings are not for the purpose of changing or influencing control of the company.
Rapid Micro Biosystems chief operating officer John J. Addington Wilson reported a sale of 4,610 shares of Class A common stock on February 9, 2026. The shares were sold at $3.7827 per share in an automatic transaction to cover tax obligations from vesting restricted stock units.
Following this transaction, Wilson directly beneficially owned 257,768 Class A shares. This total includes 29,904 shares that were acquired through the company’s employee stock purchase plan on March 14, 2025.
Rapid Micro Biosystems chief financial officer Sean M. Wirtjes reported an automatic sale of shares to cover taxes tied to equity compensation. On February 9, 2026, he sold 6,027 shares of Class A common stock at $3.7827 per share in a transaction coded as a sale. The filing states this sale was made automatically to satisfy tax obligations arising from the vesting of restricted stock units. After this transaction, Wirtjes directly owned 483,928 shares of Rapid Micro Biosystems Class A common stock.
Rapid Micro Biosystems, Inc. President and CEO Robert G. Spignesi Jr. reported an automatic sale of Class A common stock. On 02/09/2026, he sold 12,840 shares at $3.7827 per share to cover tax obligations related to vesting restricted stock units. After this transaction, he beneficially owned 962,097 shares directly.
A holder of RPID Class A common stock has filed a notice of proposed sale under Rule 144. The filing covers an intended sale of 6,027 Class A shares through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/09/2026 and an aggregate market value of $22,798.33.
The seller acquired these 6,027 shares on 02/06/2026 via restricted stock vesting from the issuer as compensation, and represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A shareholder in RPID has filed a notice of proposed sale under Rule 144 for 12,840 shares of Class A stock. These shares were acquired through restricted stock vesting on 02/06/2026 as compensation. The planned sale, valued at $48,569.87 based on market prices, is expected around 02/09/2026 through Fidelity Brokerage Services LLC on the NASDAQ. The filing notes that 39,823,026 shares of this class were outstanding, providing context for the size of the planned sale.
A shareholder of RPID filed a notice of intent to sell 4,610 shares of Class A stock under Rule 144. The planned sale, valued at $17,438.25, is to be executed through Fidelity Brokerage Services LLC on the NASDAQ around February 9, 2026. These shares were acquired on February 6, 2026 through restricted stock vesting as compensation from the issuer, indicating they are recently vested equity awards being sold into the market.
Rapid Micro Biosystems, Inc. insider entities reported a share sale and updated holdings. On February 4, 2026, Longitude Prime Fund, L.P. reported an indirect sale of 49,000 shares of Class A common stock at $3.8794 per share, leaving it with no reported shares afterward.
Separately, Longitude Venture Partners II, L.P. reported continued indirect beneficial ownership of 4,029,245 shares of Class A common stock. General partner entities and individuals associated with these funds may be deemed to share voting and dispositive power but expressly disclaim beneficial ownership beyond their pecuniary interests.
Rapid Micro Biosystems, Inc. (RPID) reported insider activity involving investment funds managed by Longitude Capital. Longitude Venture Partners II, L.P. exercised warrants for 629,032 shares of Class A common stock at $0.05 per share on a cashless basis, with 7,739 shares withheld to cover the exercise price.
After these transactions, Longitude Venture Partners II, L.P. held 4,029,245 Class A shares indirectly. Separate from this, Longitude Prime Fund, L.P. sold 46,000, 27,500 and 27,500 Class A shares on January 30, 2026, February 2, 2026 and February 3, 2026 at prices between $4.24 and $4.54 per share, leaving it with 49,000 shares owned indirectly.
The filing explains that Longitude Capital Partners II, LLC and Longitude Prime Partners, LLC are general partners of the respective funds, and individuals Patrick G. Enright and Juliet Tammenoms Bakker are managing members, all disclaiming beneficial ownership beyond their pecuniary interests.
Rapid Micro Biosystems, Inc. reported that it has released a press release with preliminary, unaudited revenue results and selected business highlights for the fourth quarter and full year ended December 31, 2025. The update is being shared through a furnished Form 8-K, which means the revenue information and commentary are provided for investors but are not deemed filed for liability purposes under certain Exchange Act provisions. The press release, attached as an exhibit, offers an early view of how the company’s business performed in late 2025 ahead of its formal financial statements.